Estamos no ar no ! Saiba mais

Kiniksa Pharmaceuticals

KNSA

Valor de mercado US$ 6,13 bi

78,59 USD

-1,35

1,69%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

78,54

-0,05

0,06%

1 dia

-1,69%

5 dias

-1,76%

1 mês

1,25%

3 meses

28,6%

6 meses

73,41%

No acumulado do ano

87,07%

1 ano

101,93%

5 anos

635,17%

10 anos

303,65%

Sobre: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Funcionários: 366

Saúde Fabricantes de medicamentos — especializados e genéricos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 50%

Neutro 37,5%

Negativo 12,5%

Zacks Investment Research

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

Investors Business Daily

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Investors Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Three Biotech Stocks Stick Out With Their Stellar Charts

Investors Business Daily

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387.

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

Zacks Investment Research

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

Zacks Investment Research

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™